A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

NCT06310967 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia
Hypouricemia, Renal

Interventions

DRUG: IG3018
OTHER: Placebo matching IG3018

Sponsor

Intelligem Therapeutics Australia Pty Ltd.